Proteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment

被引:35
作者
Singh, S. V. [1 ]
Ajay, A. K. [1 ,2 ]
Mohammad, N. [1 ]
Malvi, P. [1 ]
Chaube, B. [1 ]
Meena, A. S. [1 ,3 ]
Bhat, M. K. [1 ]
机构
[1] Natl Ctr Cell Sci, Lab 6,Savitribai Phule Pune Univ Campus, Pune 411007, Maharashtra, India
[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USA
来源
CELL DEATH & DISEASE | 2015年 / 6卷
关键词
FAS LIGAND; MACROPHAGE INFILTRATION; PERITONEAL-MACROPHAGES; MONOCLONAL-ANTIBODY; APOPTOSIS; ACTIVATION; MURINE; DEGRADATION; BORTEZOMIB; INDUCTION;
D O I
10.1038/cddis.2015.292
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Inaccessibility of drugs to poorly vascularized strata of tumor is one of the limiting factors in cancer therapy. With the advent of bystander effect (BE), it is possible to perpetuate the cellular damage from drug-exposed cells to the unexposed ones. However, the role of infiltrating tumor-associated macrophages (TAMs), an integral part of the tumor microenvironment, in further intensifying BE remains obscure. In the present study, we evaluated the effect of mitomycin C (MMC), a chemotherapeutic drug, to induce BE in cervical carcinoma. By using cervical cancer cells and differentiated macrophages, we demonstrate that MMC induces the expression of FasL via upregulation of PPAR. in both cell types (effector cells) in vitro, but it failed to induce bystander killing in cervical cancer cells. This effect was primarily owing to the proteasomal degradation of death receptors in the cervical cancer cells. Pre-treatment of cervical cancer cells with MG132, a proteasomal inhibitor, facilitates MMC-mediated bystander killing in co-culture and condition medium transfer experiments. In NOD/SCID mice bearing xenografted HeLa tumors administered with the combination of MMC and MG132, tumor progression was significantly reduced in comparison with those treated with either agent alone. FasL expression was increased in TAMs, and the enhanced level of Fas was observed in these tumor sections, thereby causing increased apoptosis. These findings suggest that restoration of death receptor-mediated apoptotic pathway in tumor cells with concomitant activation of TAMs could effectively restrict tumor growth.
引用
收藏
页码:e1934 / e1934
页数:13
相关论文
共 43 条
  • [1] Proteasome inhibition: a novel approach to cancer therapy
    Adams, J
    [J]. TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) : S49 - S54
  • [2] Novel action of paclitaxel against cancer cells: Bystander effect mediated by reactive oxygen species
    Alexandre, Jerome
    Hu, Yumin
    Lu, Weiqin
    Pelicano, Helene
    Huang, Peng
    [J]. CANCER RESEARCH, 2007, 67 (08) : 3512 - 3517
  • [3] Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells
    Bonofiglio, Daniela
    Gabriele, Sabrina
    Aquila, Saveria
    Qi, Hongyan
    Belmonte, Maria
    Catalano, Stefania
    Ando, Sebastiano
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (03) : 423 - 434
  • [4] Boyer SN, 1996, CANCER RES, V56, P4620
  • [5] Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
    Bracci, L.
    Schiavoni, G.
    Sistigu, A.
    Belardelli, F.
    [J]. CELL DEATH AND DIFFERENTIATION, 2014, 21 (01) : 15 - 25
  • [6] Bryniarski K, 2009, PHARMACOL REP, V61, P550, DOI 10.1016/S1734-1140(09)70098-2
  • [7] BUCANA CD, 1992, AM J PATHOL, V141, P1225
  • [8] A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
    Camidge, D. Ross
    Herbst, Roy S.
    Gordon, Michael S.
    Eckhardt, S. Gail
    Kurzrock, Razelle
    Durbin, Blythe
    Ing, Josephine
    Tohnya, Tanyifor M.
    Sager, Jason
    Ashkenazi, Avi
    Bray, Gordon
    Mendelson, David
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (04) : 1256 - 1263
  • [9] Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth
    Cao, Mei-Na
    Zhou, Yu-Bo
    Gao, An-Hui
    Cao, Jia-Yi
    Gao, Li-Xin
    Sheng, Li
    Xu, Lei
    Su, Ming-Bo
    Cao, Xian-Chao
    Han, Meng-meng
    Wang, Ming-Kui
    Li, Jia
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2014, 1840 (06): : 2004 - 2013
  • [10] Cellular immunity in breast cancer patients completing taxane treatment
    Carson, WE
    Shapiro, CL
    Crespin, TR
    Thornton, LM
    Andersen, BL
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (10) : 3401 - 3409